Novavax, Inc. Forecast, price target & analysts
Why the stock moved Beta
Novavax, Inc. Target price 2026 - Analyst rating & recommendation
Novavax, Inc. Classifications & Recommendation
Novavax, Inc. Price Target
| Target Price | $16.32 |
| Price | $10.00 |
| Potential |
63.20%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Novavax, Inc. 2027 .
The average Novavax, Inc. target price is $16.32.
This is
63.20%
register free of charge
$26.25
162.50%
register free of charge
$7.07
29.30%
register free of charge
|
|
| A rating was issued by 15 analysts: 10 Analysts recommend Novavax, Inc. to buy, 2 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novavax, Inc. stock has an average upside potential 2027 of
63.20%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 1,123.48 | 366.40 |
| 64.69% | 67.39% | |
| EBITDA Margin | 52.59% | -33.65% |
| 295.57% | 163.98% | |
| Net Margin | 39.19% | -32.35% |
| 242.58% | 182.55% |
11 Analysts have issued a sales forecast Novavax, Inc. 2026 . The average Novavax, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Novavax, Inc. EBITDA forecast 2026. The average Novavax, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Novavax, Inc. Analysts have issued a net profit forecast 2026. The average Novavax, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.54 | -0.72 |
| 306.50% | 128.35% | |
| P/E | negative | |
| EV/Sales | 3.35 |
11 Analysts have issued a Novavax, Inc. forecast for earnings per share. The average Novavax, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current Novavax, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | May 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jan 20 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
May 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 27 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jan 20 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 04 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
